SCHEMBL2878372

SCHEMBL2878372

COc1cccc(OC(C)=O)c1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.57
MAPK1 P28482 3/20 0.57
HSD17B10 Q99714 3/20 0.57
LMNA P02545 3/20 0.57
MAPT P10636 3/20 0.57
ALDH1A1 P00352 2/20 0.57
HPGD P15428 2/20 0.57
ALOX15 P16050 2/20 0.57
CYP3A4 P08684 2/20 0.57
TP53 P04637 2/20 0.57
ALOX12 P18054 1/20 0.57
TLR2 O60603 1/20 0.56
ERN1 O75460 1/20 0.56
TLR1 Q15399 1/20 0.56
TLR6 Q9Y2C9 1/20 0.56
TSHR P16473 3/20 0.48
TNFSF11 O14788 1/20 0.48
ESR1 P03372 1/20 0.48
ITGB3 P05106 1/20 0.48
ITGA2B P08514 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8766243 0.92 KDM4E (0.55) KDM4EMAPK1HSD17B10LMNAMAPT
SCHEMBL979737 0.84 KDM4E (0.57) KDM4EMAPK1HSD17B10LMNAMAPT
SCHEMBL1458762 0.83 HSD17B10 (0.56) KDM4EMAPK1HSD17B10LMNAMAPT
SCHEMBL15495901 0.83 LMNA (0.52) KDM4EMAPK1HSD17B10LMNAMAPT
Syringol SCHEMBL156388 0.82 KDM4E (0.80) KDM4EMAPK1HSD17B10LMNAMAPT
SCHEMBL3373821 0.82 LMNA (0.55) KDM4EMAPK1HSD17B10LMNAMAPT
SCHEMBL236191 0.81 CA12 (0.59) KDM4EHSD17B10LMNAMAPTALDH1A1
SCHEMBL29655351 0.81 CA12 (0.59) KDM4EHSD17B10LMNAMAPTALDH1A1
SCHEMBL15496053 0.81 ELANE (0.47) KDM4EMAPK1HSD17B10LMNAMAPT
Syringol SCHEMBL28128050 0.81 KDM4E (0.70) KDM4EMAPK1HSD17B10LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461384-B2 Preparation of amides from an acid and amine for intermediates in the synthesis of morphinans MALLINCKRODT LLC (US) 2013-06-11 US disclosed
US-8445682-B2 Preparation of 3,4-dihydroisoquinolines from an acid and an amine MALLINCKRODT LLC (US) 2013-05-21 US disclosed
US-8232400-B2 Preparation of 3,4-dihydroisoquinolines in the synthesis of morphinans MALLINCKRODT LLC (US) 2012-07-31 US disclosed
EP-2177504-A1 Preparation of amides from an acid and amine for intermediates in the synthesis of morphinans Mallinckrodt Inc. (US) 2010-04-21 EP disclosed
US-20100063290-A1 Preparation of 3,4-Dihydroisoquinolines from an Acid and an Amine MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) 2010-03-11 US disclosed
EP-2161253-A2 Process for the preparation of 3,4-dihydroisoquinolines in the synthesis of morphinans Mallinckrodt Inc. (US) 2010-03-10 EP disclosed
US-20090247761-A1 Preparation of 3,4-Dihydroisoquinolines in the Synthesis of Morphinans MALLINCKRODT INC. (US) 2009-10-01 US disclosed
US-20090247760-A1 Preparation of Amides from an Acid and Amine for Intermediates in the Synthesis of Morphinans MALLINCKRODT INC. (US) 2009-10-01 US disclosed
EP-2099745-A2 PREPARATION OF 3,4-DIHYDROISOQUINOLINES FROM AN ACID AND AN AMINE Mallinckrodt Inc. (US) 2009-09-16 EP disclosed
WO-2008073390-A2 PREPARATION OF 3,4-DIHYDROISOQUINOLINES FROM AN ACID AND AN AMINE MALLINCKRODT INC. (US) 2008-06-19 WO disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247761-A1 Preparation of 3,4-Dihydroisoquinolines in the Synthesis of Morphinans PNN, CDKL3, ORAI3 KDM4E 1369/4885MAPK1 2241/4885HSD17B10 3664/4885
US-20100063290-A1 Preparation of 3,4-Dihydroisoquinolines from an Acid and an Amine PNN, AOX1, PAM KDM4E 1791/4885MAPK1 1672/4885HSD17B10 3258/4885
US-20090247760-A1 Preparation of Amides from an Acid and Amine for Intermediates in the Synthesis of Morphinans PNN, PAM, NPM1 KDM4E 1893/4885MAPK1 1810/4885HSD17B10 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.